Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced that Astellas Pharma Inc. (TSE: ...
PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, ...
AI-assisted adeno-associated virus (AAV) capsid engineering has transformative potential in terms of accelerating and optimizing the development of gene therapies. That’s the view of Fangzhi Tan, PhD, ...
The FDA has granted Fast Track designation to pevifoscorvir sodium, an oral capsid assembly modulator for chronic HBV.
Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes Kits incorporate Thermo Fisher Scientific’s CaptureSelect affinity reagents for ...
The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...
Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Download Brochure Accurate viral vector characterization in ...
Researchers develop a large dodecahedral structure through the self- assembly of metal ions and peptides, with potential implications in drug delivery systems and molecular transportation. Controlling ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results